Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
The U.S. has a highly developed mixed economy that has been the world's largest nominally since about 1890. Its 2024 gross domestic product (GDP) of more than $29 trillion constituted over 25% of nominal global economic output, or 15% at purchasing power parity (PPP). The country ranks first in the world by nominal GDP, second when adjusted for purchasing power parities (PPP), and ninth by PPP-adjusted GDP per capita. In August 2026, the total U.S. federal government debt passed $40 trillion, having more than doubled in the previous decade.
In the 1960s, the BOR Code of Ethics and Standards of Conduct placed professional limitations on medical technologists requiring "A medical technologist will work at all times under the direction or supervision of a pathologist or other duly qualified and licensed doctor of medicine, such qualifications being determined on the basis of accepted medical ethics" and that "A medical technologist will not act as owner, co-owner, advisor or employee, or by means of any subterfuge, participate in an arrangement whereby an individual not regularly licensed to practice medicine is enabled to own or operate a laboratory of clinical pathology." In 1965, Janet Higgins, an ASCP certified medical technologist, was removed from the Board of Registry (BOR) because she was employed at a New Jersey laboratory where the director was a state-licensed bio-analytical laboratory director, but not a physician. Though New Jersey has never required the certification for employment, the technologist successfully sued ASCP under monopolistic restraint of trade to be reinstated to the registry with the Supreme Court of New Jersey finding that the "professional status conferred on plaintiff by her certificate is an interest of sufficient substance to warrant the protection of the court." The lawsuit, and the focus on pathologists over medical technologists spurred other medical technologist societies, such as the American Society for Medical Technology (ASMT) to promote the creation of their own certifying boards.
Drucker, Jens Holst and Svetlana Mojsov 2025: Member of the National Academy of Sciences (Section 42: Medical Physiology and Metabolism) 2025: Distinguished Medical Science Award by the National Library of Medicine - Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen 2025: Carothers Award from the American Chemical Society Delaware Section 2025: Helen Dean King Award of Wistar Institute in Philadelphia 2026: Member of the Macedonian Academy of Sciences and Arts 2026: Kimberly Prize in Biochemistry and Molecular Genetics 2026: Boulder Peptide Foundation Meinehofer Award 2026: King Faisal Prize in Medicine 2026: Broermann Medical Innovation Award - Matthias Tschöp, Svetlana Mojsov and Richard DiMarchi 2027: Elaine Redding Brinster Prize in Science or Medicine - Svetlana Mojsov and Lotte Bjerre Knudsen
Barnum Brown, assistant curator of the American Museum of Natural History, found the first partial skeleton of T. rex in eastern Wyoming in 1900. Brown found another partial skeleton in the Hell Creek Formation in Montana in 1902, comprising approximately 34 fossilized bones. Writing at the time Brown said "Quarry No. 1 contains the femur, pubes, humerus, three vertebrae and two undetermined bones of a large Carnivorous Dinosaur not described by Marsh. ... I have never seen anything like it from the Cretaceous." Henry Fairfield Osborn, president of the American Museum of Natural History, named the second skeleton T. rex in 1905. The generic name is derived from the Greek words τύραννος (tyrannos, meaning "tyrant") and σαῦρος (sauros, meaning "lizard"). Osborn used the Latin word rex, meaning "king", for the specific name. The full binomial therefore translates to "tyrant lizard the king" or "King Tyrant Lizard", emphasizing the animal's size and presumed dominance over other species of the time.
Sources: en.wikipedia.org
== Other rhEGFs == Several other products containing recombinant human EGF have been marketed. The potencies of these products can differ by the expression system used, despite all intending to match the structure of human EGF. Instead of measuring by mass, the international unit system from the World Health Organization provides a way to describe the potency-adjusted amount of rhEGF. However, the WHO does not prescribe a specific way of measuring the potency. rhEGF bioassay remains a field in active development.
=== Pre-1970 jury trials === Before they were abolished in 1970, jury trials were conducted to hear capital cases in Singapore since the British colonial era. Based on the verdict of a jury, if a person was found guilty, the judge would convict and impose a penalty to the defendant in accordance to the charge he or she was found guilty of. One notable case in which a person was sentenced to death in a jury trial was the trial of Sunny Ang Soo Suan, who allegedly murdered his girlfriend Jenny Cheok Cheng Kid during a scuba diving trip in 1963. Despite the circumstantial evidence and the absence of the victim's body, the seven-men jury unanimously found Ang guilty of murder and sentenced him to death. Ang was eventually hanged on 6 February 1967 after he lost all his appeals to both the Court of Appeal and the Privy Council, and the failure of his clemency plea to President Yusof Ishak. The first person to be tried before two judges in the High Court and sentenced to death for a capital case was armed robber Teo Cheng Leong, who was found guilty and sentenced in February 1970 for unlawfully discharging a firearm twice when he fired two missed shots at a police officer. Another notable case was the kidnapping and murder of Ong Beang Leck, the son of a rich tycoon. Five men were involved in the abduction and they had murdered Ong after luring him into a rented car on 24 May 1968. Three of the kidnappers were found guilty of murder and sentenced to death in June 1970.
=== Australia and New Zealand === There are 15 recognised specialty medical Colleges in Australia. The majority of these are Australasian Colleges and therefore also oversee New Zealand specialist doctors. These Colleges are:
=== Biotin === Subsequently, with Vincent du Vigneaud, he used the newly developed technique of chromatography that he had learned while a student in Zürich, to isolate and then crystallize biotin. This work began a theme that continued throughout his career of determining the importance of sulfur in biologically active structures. He applied this to peptides as well.
Methyl blue is a chemical compound with the molecular formula C37H27N3Na2O9S3. It is used as a stain in histology, and stains collagen blue in tissue sections. It can be used in some differential staining techniques such as Mallory's trichrome stain and Gömöri trichrome stain, and can be used to mediate electron transfer in microbial fuel cells. Fungal cell walls are also stained by methyl blue. Methyl blue is also available in mixture with water blue, under name Aniline Blue WS, Aniline blue, China blue, or Soluble blue; and in a solution of phenol, glycerol, and lactic acid under the name Lactophenol cotton blue (LPCB), which is used for microscopic visualization of fungi.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.